Ellen Rosenberg, an insider at Amicus Therapeutics Inc (FOLD), purchased 543,710 shares on November 24, 2025, at a price of $5.13 per share, totaling $2.79 million. Following this transaction, Rosenberg holds the same number of shares in the company.
Amicus Therapeutics, headquartered in Princeton, New Jersey, focuses on developing treatments for metabolic diseases. The company has a market cap of $3.1 billion and reported an EPS of -0.05 for the trailing twelve months. Its upcoming earnings report is scheduled for July 29, 2026, with an estimated EPS of $0.06 and revenue of $184.7 million.
Insider transactions, such as this purchase, can provide insight into executives' confidence in their company's future. However, it is essential for investors to consider a broader context, including patterns of activity among multiple insiders and fundamental factors, rather than relying on isolated transactions alone.
Amicus Therapeutics markets Galafold, the first oral monotherapy for Fabry disease, and Pombiliti + Opfolda, a treatment for late-onset Pompe disease. Clinical studies are ongoing for both therapies in pediatric populations.